Q1 FY27: revenue jumps nearly 7x YoY, PAT slips

Revenue growth above 20%Results View source PDF Explain this filing

Price

Loading chart…

▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.

Price reactionminutes from the announcement price · days from the prior close

+2.4%Reaction day

₹0.41

prior close

₹0.42

announcement price

After-mkt

timing

Nifty Microcap 250market · in no size index; the smallest one is used+0.1%+2.4% vs market

Pharmaceuticals peers, median of 166sector-0.4%+2.8% vs sector

On the reaction day the stock moved 2.4 pts more than Nifty Microcap 250 and 2.8 pts more than its Pharmaceuticals peers, over the same two closes: a difference in percentage points, not a measure of what the filing did.

Minutes after the announcementfrom the announcement price · no benchmark

Stock

+0.0

10m

-2.4

15m

-2.4

30m

-2.4

Sessions after the filingfrom the prior close

StockMarketvs marketSectorvs sector

Reaction day

+2.4+0.1+2.4-0.4+2.8

Next day

+2.4+0.2+2.2-0.5+2.9

+2.4+0.6+1.9-0.6+3.0

-2.4-0.0-2.4-1.3-1.1

+0.0+0.5-0.5-0.9+0.9

-4.9+0.8-5.6-0.4-4.5

+0.0+0.6-0.6-0.9+0.9

15d

-2.4+1.3-3.7+0.0-2.5

-7.3-1.4-6.0-0.1-7.2

-12.2-0.6-11.6-2.6-9.5

—————

UpDownMarket · Nifty Microcap 250Sector · Pharmaceuticals peers, median of 166Pending

Minute windows have no benchmark: there is no intraday index history to compare against.

AI summary

Revenue from operations surged to Rs 3,101.15 lakhs in Q1 FY27 from Rs 455.62 lakhs in Q1 FY26, a jump of about 6.8 times. However, PAT dipped to Rs 12.30 lakhs from Rs 21.51 lakhs YoY. Total expenses climbed to Rs 3,096.88 lakhs, leaving very thin margins. Full year FY26 had ended with a loss of Rs 628.72 lakhs against revenue of Rs 14,175.23 lakhs. Auditor Motilal & Associates LLP gave an unqualified limited review.

Likely market impact

Strong top-line growth but wafer-thin margins and a loss-making FY26. Watch for sustained profitability before getting excited.